COURSE CREDITS & HOURS
1.5 AMA PRA Category 1 Credits™15 ACPE Credits
15.0 Contact Hours
COURSE FEES
3 Day Fee: $675
2 Day Fee: $575
1 Day Fee: $475
Conference Surcharge if not staying on site at hotel: $50.00 (see Conference Policies)
Live Stream Webcast Registration:
3 Day Fee: $550
2 Day Fee: $450
1 Day Fee: $350
Live Stream Webcast registration includes live conference streaming, access to online course materials and documentation of continuing education credit*.
Spouses, family and friends are welcome and do not need to register unless they attend the educational sessions. Special seminar fees are available for non-professional accompanying persons who wish to attend one or more session (no special receipt, certification or credit issued).
TARGET AUDIENCE
PROGRAM PURPOSE
Hot Topics in Infectious Diseases: New Antimicrobials, Penicillin Allergy De-labeling, Shorter Durations of Therapy, and more IV to PO conversion in complicated infections
5 hours | Wednesday, 6/9/2021
Check-in and Breakfast: 7:30AM PST
Educational Session: 8:00AM 1:30PM PST
At the conclusion of this program, the participant will be able to:
- Review various newer antimicrobials that have been FDA-approved.
- Evaluate these agents critically for use in clinical practice.
- Discuss penicillin allergies including long-term implications.
- Describe process and recent data supporting intervention strategies to de-label patients.
- Describe disease states for which shorter durations of therapy data are growing.
Hot Topics in Ambulatory Care: New Asthma Guidelines, Migraine Prophylaxis including CGRP antagonists, and COVID-19 for the Primary Care Provider
5 hours | Thursday, 6/10/2021
Check-in and Breakfast: 7:30AM PST
Educational Session: 8:00AM 1:30PM PST
At the conclusion of this program, the participant will be able to:
- Describe new recommendations to recently published asthma guidelines.
- Discuss changes in asthma medication recommendations.
- Discuss current role of traditional agents for migraine prophylaxis.
- Describe role of newer CGRP antagonists within migraine prophylaxis.
- Review acute effects of COVID-19 on the primary care provider.
- Provide guidance in managing long-term complications of COVID-19 for the primary care provider.
Preventive Cardiovascular Pharmacotherapy Update: A Case-Based Approach
5 hours | Friday, 6/11/2021
Check-in and Breakfast: 7:30AM PST
Educational Session: 8:00AM 1:30PM PST
At the conclusion of this program, the participant will be able to:
- Review medications and lifestyle modifications that are recommended for the treatment and prevention of cardiovascular disease.
- Explain recommendations from the American College of Cardiology/American Heart Association guidelines for treatment of patients with hypertension, hypercholesterolemia, heart failure with reduced ejection fraction, peripheral arterial disease and atrial fibrillation.
- Formulate a care plan for patients with resistant hypertension based on the 2018 American Heart Association scientific statement.
- Describe the evidence supporting bedtime dosing of antihypertensive medications.
- Apply the treatment approaches recommended in the 2018 ACC-AHA cholesterol guideline to patients with hypercholesterolemia.
- Define the evidence and role in therapy of nonstatin medications in the treatment of hypercholesterolemia.
- Examine results from cardiovascular outcome trials evaluating the use of angiotensinneprilysin inhibition in heart failure with reduce ejection fraction.
- Compare and contrast the evidence and guideline recommendations supporting the use of antiplatelet therapy for primary and secondary prevention patients.
- Examine the evidence-based CV risk reduction benefits of medications used to treat type 2 diabetes.
- Create treatment plans that reduce the risk of cardiovascular disease.